Tolerability and Pharmacokinetics of Metformin and Metformin Extended Release (ER)
- Registration Number
- NCT00941239
- Lead Sponsor
- Laboratorios Silanes S.A. de C.V.
- Brief Summary
The purpose of this study is to determine the gastric tolerability and the pharmacokinetics of an extended release metformin compared with an immediate release metformin in healthy subjects.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
- Mexican healthy subjects with normal clinical laboratory test results and imaging (hematology, blood chemistry, urine test, VDRL, Hepatitis B, HIV, chest radiography and electrocardiogram)
Exclusion Criteria
- Familiar or personal history of diabetes
- History of drug or alcohol abuse within the 2 years prior to the study
- A smoking habit greater than 10 cigarettes per day
- History of allergy to the study drugs
- Intercurrent disease
- Intercurrent treatment with any drug
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description metformin ER metformin ER Extended Release Metformin metformin metformin Immediate release metformin
- Primary Outcome Measures
Name Time Method Plasmatic drug concentration 48 hours (7.5, 15,30,45,60,75,90,120,150,180,205,240,360,480,600,720,1440,2880 min and days : 3,5,7,14,21,28,30,35)
- Secondary Outcome Measures
Name Time Method Lanza score 30 days (0 and 30) plasmatic glucose 30 days (0, 6, 12 and 18 hours and days: 2,5,7,14,21,28,30 and 35) Glycated hemoglobin 30 days (days: 0, 14 and 30)
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of metformin ER in gastric tolerability compared to immediate release formulations?
How does metformin ER's pharmacokinetic profile compare to standard metformin in healthy subjects?
Are there specific biomarkers that correlate with improved gastric tolerability in metformin ER trials?
What adverse events are associated with metformin ER versus immediate release metformin in phase 1 studies?
How do extended release formulations of biguanides like metformin ER influence drug absorption and therapeutic outcomes in diabetes management?
Trial Locations
- Locations (1)
Pharmacology and toxicology department, UANL
🇲🇽Monterrey, Nuevo León, Mexico
Pharmacology and toxicology department, UANL🇲🇽Monterrey, Nuevo León, Mexico